HomepageLCTX • NYSEAMERICAN
add
BioTime
$ 0,58
Voorbeurs:(2,34%)-0,014
$ 0,57
Gesloten: 13 jan, 04:21:18 GMT-5 · USD · NYSEAMERICAN · Disclaimer
Vorige slotkoers
$ 0,53
Dag-range
$ 0,51 - $ 0,58
Jaar-range
$ 0,48 - $ 1,61
Beurswaarde
128,37 mln. USD
Gem. volume
3,17 mln.
Koers/winst
-
Dividendrendement
-
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 3,78 mln. | 203,29% |
Bedrijfskosten | 4,41 mln. | 9,13% |
Netto inkomsten | -3,03 mln. | 57,33% |
Netto winstmarge | -80,29 | 85,93% |
Winst per aandeel | -0,02 | 50,37% |
EBITDA | -3,70 mln. | 43,35% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 32,71 mln. | -20,86% |
Totale activa | 96,59 mln. | -9,00% |
Totale passiva | 31,80 mln. | -19,48% |
Totaal aandelenvermogen | 64,79 mln. | — |
Uitstaande aandelen | 188,84 mln. | — |
Koers-boekwaardeverhouding | 1,52 | — |
Rendement op activa | -9,63% | — |
Rendement op kapitaal | -13,98% | — |
Kasstroom
Nettomutatie in liquide middelen
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -3,03 mln. | 57,33% |
Operationele kasstroom | -5,79 mln. | -14,89% |
Kasstroom uit beleggingen | 3,89 mln. | 83,22% |
Kasstroom uit financiering | -3,00K | -100,37% |
Nettomutatie in liquide middelen | -1,86 mln. | 23,86% |
Vrije kasstroom | -2,27 mln. | 12,27% |
Over
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Opgericht
1990
Website
Werknemers
72